- Home
- GUG vs MGTX Comparison
GUG vs MGTX Comparison
Compare GUG & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUG
- MGTX
- Stock Information
- Founded
- GUG 2021
- MGTX 2015
- Country
- GUG United States
- MGTX United States
- Employees
- GUG N/A
- MGTX N/A
- Industry
- GUG Trusts Except Educational Religious and Charitable
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GUG Finance
- MGTX Health Care
- Exchange
- GUG Nasdaq
- MGTX Nasdaq
- Market Cap
- GUG 514.2M
- MGTX 479.9M
- IPO Year
- GUG N/A
- MGTX N/A
- Fundamental
- Price
- GUG $15.51
- MGTX $7.30
- Analyst Decision
- GUG
- MGTX Strong Buy
- Analyst Count
- GUG 0
- MGTX 2
- Target Price
- GUG N/A
- MGTX $23.50
- AVG Volume (30 Days)
- GUG 108.9K
- MGTX 257.4K
- Earning Date
- GUG 01-01-0001
- MGTX 03-13-2025
- Dividend Yield
- GUG 9.67%
- MGTX N/A
- EPS Growth
- GUG N/A
- MGTX N/A
- EPS
- GUG N/A
- MGTX N/A
- Revenue
- GUG N/A
- MGTX $13,929,000.00
- Revenue This Year
- GUG N/A
- MGTX N/A
- Revenue Next Year
- GUG N/A
- MGTX $1,391.84
- P/E Ratio
- GUG N/A
- MGTX N/A
- Revenue Growth
- GUG N/A
- MGTX 108.24
- 52 Week Low
- GUG $12.71
- MGTX $3.85
- 52 Week High
- GUG $15.06
- MGTX $7.80
- Technical
- Relative Strength Index (RSI)
- GUG 48.31
- MGTX 66.58
- Support Level
- GUG $15.47
- MGTX $6.72
- Resistance Level
- GUG $15.62
- MGTX $7.06
- Average True Range (ATR)
- GUG 0.18
- MGTX 0.37
- MACD
- GUG -0.04
- MGTX 0.05
- Stochastic Oscillator
- GUG 13.56
- MGTX 71.61
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.